NFKB1 and metabolic dysfunction-associated steatohepatitis: To further investigate the effects of tipifarnib on inflammation in HCC cells under NASH-like conditions, we evaluated the expression of NF-κB and TGF-β, a master mediator of closely linking inflammation and cancer [34,35].